Maxim Group analyst Naz Rahman maintained a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) yesterday and set a price target of $2.00. The company’s shares opened today at $0.50.
Rahman covers the Healthcare sector, focusing on stocks such as Clene, Quoin Pharmaceuticals, and Virpax Pharmaceuticals. According to TipRanks, Rahman has an average return of 4.3% and a 32.77% success rate on recommended stocks.
Quoin Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
See Insiders’ Hot Stocks on TipRanks >>
QNRX market cap is currently $2.36M and has a P/E ratio of -0.08.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Read More on QNRX:
- Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
- Quoin Pharmaceuticals doses first patient in open label Netherton trial
- Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial
- Quoin Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
